⚠️ For research and laboratory use only. Not for human or animal use.

⚠️ For research and laboratory use only. Not for human or animal use.

Tirzepatide – Pre-Filled Injectable Pen

Name: Tirzepatide Peptide GLP1 - perdita di peso | PepticoreAminos
Availability: InStock

Price range: 250,00 € through 420,00 €

The Tirzepatide, the active ingredient of Mounjaro, is a dual-action peptide molecule
(GIP/GLP-1). The pre-filled Pepticore Aminos pens are single-use, ready-to-use devices
equipped with a controlled delivery mechanism and a volume inspection window.

Product Features

Sterile, pre-filled pens ready for use.
Visible graduated scale for volume control.
Ideal for studies on metabolism, glycemic control and GIP/GLP-1 research.

Available Variants

Select the dosage from the menu. Equivalent in 2.5 mg doses:

Variant	Total Content	Volume	2,5mg Doses
10 mg / 1 ml	10 mg	1.0 ml	4 doses
15 mg / 1.5 ml	15 mg	1.5 ml	6 doses
30 mg / 3 ml	30 mg	3.0 ml	12 doses
60 mg / 3 ml	60 mg	3.0 ml	24 doses

*Dosi indicative calcolate su frazioni da 2,5 mg ciascuna.

Note

Product intended for research use. Not intended for diagnosis, treatment, or prevention of diseases.

3 products 5% OFF

237,50 € / each ~~250,00 €~~

6 products 8% OFF

230,00 € / each ~~250,00 €~~

10 products 12% OFF

220,00 € / each ~~250,00 €~~

dosaggio

Clear

SKU: N/A Categories: Metabolic & Weight Loss, Ready-to-Use Peptides – Pens Brand: Pepticore Aminos

Laboratory analysis available (COA)Other tests for currently available dosages of this product:

Latest tested batch: Tirzepatide pen 30mg: PC-TIZ3-0611T — 30mg/3ml

Download latest COA

Pay With

Tirzepatide

Dual GIP/GLP-1 peptide for research on diabetes, obesity, and metabolism.

What is Tirzepatide

Tirzepatide is a next-generation peptide molecule developed for the treatment of type 2 diabetes and obesity. It is the active compound in the commercial drug Mounjaro, approved worldwide as a dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This combination of hormonal targets allows simultaneous action on blood glucose regulation, lipid metabolism, and appetite control.

Unlike previous GLP-1 agonists, Tirzepatide produces a synergistic effect that improves glycemic control, promotes significant and long-lasting weight loss, and enhances the body’s overall energy efficiency. In subjects with obesity, treatment with Tirzepatide has shown body weight reductions of up to 22.5% over 72 weeks, as reported in the reference study SURMOUNT-1 (NEJM 2022).

Mechanism of Action: synergy between GIP and GLP-1

Tirzepatide mimics the combined action of two natural intestinal hormones, GIP and GLP-1, known as incretins. These hormones are secreted after meals and contribute to the regulation of glucose and fat metabolism. By acting on both receptors, Tirzepatide amplifies the signals that control insulin secretion, reduces glucagon levels, and modulates the brain centers of appetite.

GIP Receptor

The GIP receptor stimulates the pancreas to release insulin only when blood glucose levels are high, minimizing the risk of hypoglycemia. It also participates in fat metabolism by influencing the use of fatty acids as an energy source. In combination with GLP-1, this pathway promotes the reduction of visceral fat, the type most closely associated with cardiovascular risk and insulin resistance.

GLP-1 Receptor

Activation of the GLP-1 receptor reduces hunger, slows gastric emptying, and stimulates insulin secretion in response to glucose. At the same time, it inhibits the release of glucagon, thereby lowering blood sugar levels. The combined effect improves HbA1c, stabilizes fasting glucose, and facilitates the maintenance of a prolonged caloric deficit.

This dual endocrine action underlies the success of Tirzepatide, combining the antidiabetic properties of GLP-1 with a broader metabolic impact mediated by GIP. Clinical results also suggest a potential role in improving vascular health, reducing blood pressure, and lowering systemic inflammatory markers

Main Observed Benefits

Optimized glycemic control through enhanced glucose-dependent insulin secretion.
Sustained weight loss and reduction of visceral fat mass.
Improved lipid profile with lower LDL cholesterol and higher HDL.
Reduced appetite and prolonged post-meal satiety.
Positive effects on energy metabolism and cardiovascular function.

Comparison with Other Incretin Agonists

Tirzepatide belongs to the same pharmacological class as Semaglutide and the newer Retatrutide, but differs in the number of receptors activated and the intensity of the metabolic effect. Comparative studies have shown that Tirzepatide outperforms Semaglutide in improving glycemic control and achieving greater weight reduction, as demonstrated in the SURPASS-2 (NEJM 2021) trial.

Drug	Activated Receptors	Main Effects	Average Weight Loss (Clinical Data)
Semaglutide	GLP-1	Satiety, slower gastric emptying, glycemic control	≈ 15% in 68 weeks
Tirzepatide	GLP-1 + GIP	Dual action on appetite, glucose, and lipid metabolism	≈ 22,5% in 72 weeks(SURMOUNT-1)
Retatrutide	GLP-1 + GIP + glucagon	Higher energy expenditure and fat oxidation	≈ 24% in 48 weeks(Phase 2, preliminary data)

Scientific References

Notes and Warnings

The Tirzepatide supplied by Pepticore Aminos is intended for research and laboratory use only. It is not approved for human or animal consumption and must not be used as a medicinal or diagnostic product. All information is provided for research and educational purposes only and is based on publicly available clinical data.

dosaggio	10mg/1ml, 15mg/1.5ml, 15mg/2.5ml, 30mg/3ml, 60mg/3ml

Peptide Technical Data

Product Name	Tirzepatide
CAS Number	2023788-19-2
Sequence (Truncated)	Y1-His-Ala-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH
Molecular Formula	C₂₈₉H₄₄₀N₇₈O₉₅
Molecular Weight	~5660.65 g/mol
Purity	≥99% (HPLC validated)
Synthesis Method	Recombinant peptide or SPPS variant, depending on supplier
Format	Lyophilized powder
Appearance	White to off-white powder
Solubility	Soluble in water, PBS, or minimal acid buffers
Stability & Storage	−20°C up to 18 months; post-reconstitution: 4°C ≤10 days; −20°C ≤6 months
Regulatory Status	Research use only; not for human consumption

Pens Storage

Storage Instructions – Pre-Filled Pens

Refrigeration: store at 2–8 °C to preserve quality and effectiveness.

Shelf life: the product maintains full stability and effectiveness for up to 12 months when properly refrigerated.

Temperature tolerance: the product remains stable up to 25 °C but should not be exposed to higher temperatures.

Avoid freezing: do not freeze; freezing may compromise the stability and effectiveness of the active ingredient.

Storage After Delivery

Store the pens in a refrigerated environment and away from direct light.

For use within a few weeks, regular household refrigeration (< 8 °C) is sufficient. Avoid direct exposure to heat sources.

Stability Notes

The pre-filled pens contain solutions already reconstituted and ready to use, therefore they require greater thermal care compared to lyophilized peptides.

Proper maintenance of the cold chain ensures maximum efficacy and molecular integrity of the active ingredient.

Disclaimer - For Research Use Only

I prodotti offerti da Pepticore Aminos sono destinati esclusivamente all’uso in ambito di ricerca e laboratorio e sono venduti unicamente a professionisti, istituti o enti qualificati. Tali prodotti non sono destinati al consumo umano o veterinario, né a qualsiasi applicazione che coinvolga organismi viventi, inclusi – a titolo esemplificativo – scopi diagnostici, terapeutici o ricreativi. By making a purchase, the customer declares that:

they are a qualified professional or entity, possessing the necessary competence, training, and facilities for the safe handling of chemical reagents;
they will use the product in full compliance with all applicable local, national, and European Union laws and regulations;
they will adopt appropriate safety measures during all stages of handling, storage, and disposal.

Prohibited uses:

The product must not be used as an Active Pharmaceutical Ingredient (API) in the manufacturing or preparation of medicines intended for humans or animals;
Any direct administration or use on humans or animals is strictly prohibited;
Pepticore Aminos does not endorse or permit the use of its products for the production, testing, or development of illegal substances.

Regulatory compliance: Pepticore Aminos non dichiara né implica che i prodotti siano approvati dall’Agenzia Europea per i Medicinali (EMA), dalla Food and Drug Administration (FDA) o da altre autorità regolatorie. Le informazioni riportate sono fornite esclusivamente a fini informativi e scientifici. Questi prodotti non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. Liability: L’acquirente si assume ogni responsabilità per la manipolazione, conservazione e utilizzo del prodotto in condizioni sicure e conformi alla legge. Pepticore Aminos non potrà essere ritenuta responsabile per danni diretti o indiretti derivanti da un uso improprio, dallo stoccaggio non corretto o da un utilizzo non autorizzato del prodotto. Pepticore Aminos si riserva il diritto di rifiutare la vendita a qualsiasi individuo o ente sospettato di uso improprio dei propri prodotti. In caso di dubbi sull’uso sicuro e legittimo del prodotto, si raccomanda di consultare un professionista qualificato esperto in ricerca di laboratorio.